Ann: Business Activity Statement & Appendix 4C - Dec-2023 Qtr, page-10

First 10 Last

Share
Profile

Follow
The25thBam

35 Posts.

44

12/02/24

17:55

Post #: 72365863
Share

Originally posted by doctornoh: ↑

thanks for the post.

Some comments. On the Soul Patts loan there is no option to repay early- EOS was clear in this in the investor update- without paying interest in full. So we are loaded with this debt for the foreseeable future. Just shows you how desperate EOS was at the time to keep afloat. Although people forget that this was COVID and so a bit of bad luck involved as well.

Full year FY23 revenue guidance is $210-$230m- 1H fy23 revenue was $74m.

That a big boost in the 2H- hopefully this means full year EBITDA may be a positive number as we know the Western European contract was delivered using existing stock and would have fallen to the revenue line this period.

Strong operational positive cash flows disclosed in the latest 4C is a good indicator.

The CEO/CFO were also clear in comments in the recent recording that contract award periods are coming down and there are a lot of mission critical type contracts that are needed to fulfill current wartime operational needs. So they say quicker contract awards and more pricing power. In any case time will tell as to revenue generation in FY24 as really an arms company should be making hay right now,

Expand

Good callout doc, long time fan and have learned a lot from you over the years. Maybe our patience will be rewarded this year

EOS Price at posting: $1.63 Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

OCC

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

PAR

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

First 10 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $2.72		Change 0.070(2.64%)		Mkt cap ! $524.8M

Open	High	Low	Value	Volume
$2.68	$2.78	$2.67	$2.114M	777.0K

Buyers (Bids)

No.	Vol.	Price($)
5	8373	$2.71

Sellers (Offers)

Price($)	Vol.	No.
$2.73	9363	3

View Market Depth

No.	Vol.	Price($)
6	9078	2.710
6	11166	2.700
5	13974	2.690
6	47720	2.680
5	11326	2.670

Price($)	Vol.	No.
2.730	9363	3
2.740	6962	4
2.750	33127	5
2.760	1542	1
2.770	7306	3

Last trade - 12.19pm 27/06/2025 (20 minute delay)

EOS (ASX) Chart

Ann: Business Activity Statement & Appendix 4C - Dec-2023 Qtr, page-10

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Australia’s gas crisis is here – and dying coal plants aren’t helping

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Business Activity Statement & Appendix 4C - Dec-2023 Qtr, page-10

Top Stories

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Australia’s gas crisis is here – and dying coal plants aren’t helping

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News